Prostate tumors therapy targets

Y. Zhang, R. Stein, W. Wang, M. Steiner, and Y. Lu, Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy, Tumor Targeting 4 158 (1999). 

In addition to differences between tumors and their environment, the neo vascular phenotype itself may differ between tissues. A variety of vascular morphologies has been discussed above, and specific molecules expressed by the neovasculature may also vary. For example, binding of the antiangiogenic factor endostatin was found to almost all bladder tumor vessels, three quarters of the vessels in prostatic carcinomas, and only 11% of renal tumor vessels [63]. VEGFR3, which, in most tissues, is restricted to lymphatics, has been identified in the new blood vessels of inflamed synovium [26]. These and other characteristics of different neo vascular beds may contribute to heterogeneous responses to therapies that target the vasculature. 

Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. / Clin Oncol. 2007 25 540. 

---